Table 3.
Comparison of autoantibodies among patients with different cGVHD grade.
| Chronic GVHD grade | |||||||
|---|---|---|---|---|---|---|---|
|
No (n = 42) |
Mild (n = 11) |
Moderate/Severe (n = 31) |
P | ||||
| Autoantibodies | Negative | Positive | Negative | Positive | Negative | Positive | |
| Anti-Ro52 | 41 (97.6) | 1 (2.4) | 9 (81.8) | 2 (18.2) | 21 (67.7) | 10 (32.3) | <0.01 |
| ANA | 35 (83.3) | 7 (16.7) | 9 (81.8) | 2 (18.2) | 12 (38.7) | 19 (61.3) | <0.001 |
| Anti-Rib-P | 42 (100.0) | 0 (0.0) | 11 (100.0) | 0 (0.0) | 30 (96.8) | 1 (3.2) | 0.42 |
| AHA | 42 (100.0) | 0 (0.0) | 10 (90.9) | 1 (9.1) | 31 (100.0) | 0 (0.0) | <0.05 |
| Anti-PM/Scl | 42 (100.0) | 0 (0.0) | 11 (100.0) | 0 (0.0) | 30 (96.8) | 1 (3.2) | 0.42 |
| Anti-Jo-1 | 42 (100.0) | 0 (0.0) | 11 (100.0) | 0 (0.0) | 30 (96.8) | 1 (3.2) | 0.42 |
| AMA-M2 | 42 (100.0) | 0 (0.0) | 11 (100.0) | 0 (0.0) | 29 (93.5) | 2 (6.5) | 0.17 |
| Anti-CENP-B | 42 (100.0) | 0 (0.0) | 11 (100.0) | 0 (0.0) | 30 (96.8) | 1 (3.2) | 0.42 |
GVHD, graft-vs.-host disease; anti-Ro52, anti-Ro52 autoantibodies; ANA, anti-nuclear autoantibodies; anti-Rib-P, anti-ribosomal P protein autoantibodies; AHA, anti-histone autoantibodies; anti-PM/Scl, anti-polymyositis/scleroderma autoantibodies; anti-Jo-1, anti-histidyl tRNA synthetase autoantibodies; AMA-M2, anti-mitochondrial autoantibodies type 2; anti-CENP-B, anti-centromere-B autoantibodies.